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Human papillomavirus type 16 (HPV-16) E2 protein negatively regulates transcription of the E6 and E7 genes. This study was done to test the
hypothesis that methylation of the HPV 16 long control region (LCR) is overrepresented among cervical cancer (CaCx) cases compared to
cytologically normal controls harboring intact E2 gene. Methylation of the E2 binding site (E2BS-I), proximal to the P97 promoter, was assessed
by HpaII/ MspI restriction digestion while McrBC digestion was used to assess LCR-E6 (7289–540) for 57 CaCx samples and 15 normal controls.
E2BS-I methylation was found to be significantly higher (56.14%) in cases compared to (20%) controls [ORage-adjusted (95% CI): 4.53 (1.05–
19.43) p=0.042]. The difference between cases (54.39%) and controls (40%) with respect to LCR-E6 methylation status [ORage-adjusted (95% CI):
1.77(0.5–6.3); p=0.38] was not significant. Sequencing of a randomly selected set of 13 methylated malignant samples revealed absence or rare
presence, of methylation at CpGs 7579, 7535, 7683 and 7862 respectively. Methylation was found to be more at CpGs within E2 binding sites
proximal to the P97 promoter. These results indicate the involvement of E2 binding site methylation in presence of intact E2, leading to loss of E2
repressor activity in CaCx.
© 2006 Elsevier Inc. All rights reserved.Keywords: Cervical cancer; HPV16 genome methylation; Intact E2 gene; E2 binding siteIntroduction
Human papillomavirus type 16 (HPV16) infection is the
major oncogenic type found to be associated with cervical
cancer (CaCx) worldwide. Infection of the cervical epithelium
with HPV could lead to viral clearance or persistence, thereby
determining the onset of CaCx. The host defense machinery
plays a pivotal role in this respect, while the various other factors
that determine the fate of the virus still remain unknown. Of
these, the most plausible explanation seems to tether with HPV
oncogene transcription that is further modulated by various
factors, one such being the inactivation of E2 (Tan et al., 1994).
The E2 protein on binding to the HPV16 promoter region at
specific sites denoted as E2 binding sites (E2BS) blocks the
binding of transcription factors thus preventing E6 and E7
transcription. In the high-risk HPV genomes, four highly con-
served E2BSs are located in the viral long control region (LCR),⁎ Corresponding author. Fax: +91 33 2577 6680/3049.
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doi:10.1016/j.virol.2006.06.018which is rich in cis elements. These E2BSs are located close to
DNA binding sites of various cellular transcription factors.
Various studies have reported the disruption of the E2 gene
as a prerequisite for uncontrolled expression of the viral
oncoproteins (Jeon and Lambert, 1995; Lukaszuk et al., 2003).
But HPV16 harboring intact E2 in the episomal form is often
found to coexist with disrupted forms in CaCx. (Matsukura et
al., 1989). In fact, a few studies have also reported an increased
frequency of intact episomal HPV16 DNA in CaCx (Cullen et
al., 1991), reflecting a lack of repression of E6 and E7 genes by
intact E2. Ironically in our previous study, undisrupted E2 gene
was found in 60% CaCx cases (Bhattacharjee and Sengupta,
2006). We further identified a single nucleotide change, 7450
T>C variation within the E2 binding site towards the 5′ end
of LCR (E2BS-IV), in samples harboring undisrupted E2. This
variation was significantly overrepresented among HPV16-
positive CaCx cases, where the virus belonged to the E lineage.
Based on such finding, we hypothesized that this polymorphism
is likely to have strong biological plausibility towards
facilitating cell transformation, probably through enhanced
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activity of E2.
E2BSs, because they contain CpG dinucleotides within the
conserved palindromic sequences, are potential sites for DNA
methylation in the mammalian host cell. It has already been
identified from in vitro analysis that HPV16 E2 binding site
methylation prevents E2 binding (Thain et al., 1996; Kim et al.,
2003). Such phenomenon in vivo could therefore lead to loss of
E2 repression coupled with sustained E6/E7 expression in cases
harboring HPV16 genomes with intact E2 gene. The objective
of this study was therefore to test the hypothesis that
methylation of the HPV 16 long control region (LCR) involving
E2BSs in samples harboring intact E2 gene, is overrepresented
among CaCx cases compared to cytologically normal controls.
Hence, we first determined the methylation status of E2 binding
site proximal to P97 promoter in HPV16-positive cases and
controls followed by the methylation status of CpGs within
LCR-E6 segment of samples harboring intact HPV16 E2 gene.
We adopted the second approach to test the hypothesis put
forward by Badal et al. (2003) that hypomethylation of LCR
and E6 regions correlated with carcinogenic progression of
HPV16 infected cervical cells by comparing CaCx cases with
cytologically normal controls harboring intact E2.
Results
Analysis of methylation status of HPV16 DNA by restriction
enzyme digestion and PCR
The typical results of E2BS-I methylation proximal to P97
promoter as analyzed by HpaII/MspI, McrBC digestion and
PCR are shown in Fig. 1 and methylation status for all the
samples are summarized in Table 1. E2BS-I methylation was
found in 20% (3/15) of normal subjects while a substantially
higher proportion of 56.14% (32/57) CaCx cases were found toFig. 1. McrBC and HpaII digested products after PCR amplification with LCR-E6 pr
agarose gel. The lane labeled HL3 contains Hyperladder III (Bioline), MS is McrB
malignant samples (T132, T50 and T121 respectively) digested with McrBC and H1,
ladder. UM and M mentioned are abbreviations for methylated and unmethylated Charbor such methylation. This difference was statistically
significant [ORage-adjusted (95% CI) 4.53(1.05–19.43); Fisher's
p value=0.042].
LCR-E6 methylation, on the other hand, was found in 40%
(6/15) of normal subjects, whereas 54.39% (31/57) of CaCx
samples were found to be methylated. Although proportionately
higher among the CaCx cases, LCR-E6 methylation status
failed to be significantly [ORage-adjusted (95% CI) 1.77 (0.5–
6.3); Fisher's p value=0.38] associated with the disease. Lack
of association of LCR-E6 methylation was also evident when
stratified analysis was performed comparing cases and controls
within groups lacking or harboring E2BS-I methylation.
LCR-E6 methylation was found in 33.3% (1/3) of the
controls with E2BS-I methylation and 41.67% (5/12) of similar
unmethylated controls. Likewise, LCR-E6 methylation was
found in 46.88% (15/32) cases harboring E2BS-I methylation in
contrast to 68% (17/25) cases lacking E2BS-I methylation.
Thus, among the CaCx cases, LCR-E6 methylation was higher
in those cases that lacked E2BS-I methylation (Fisher's p
value=0.06) in contrast to those that harbored E2B-I methyla-
tion. However, a similar analysis revealed a non-significant
difference (Fisher's p value=0.47) in LCR-E6 methylation
among control samples harboring E2BS-I methylation or not.
Analysis of the methylation status of HPV16 LCR based on
nucleotide sequencing of modified viral DNA
In order to ascertain the involvement of methylation of other
key sites within the enhancer-promoter in the LCR, a subset of
13 methylated samples as revealed by McrBC restriction
digestion were subjected to direct sequencing of the amplicons
after bisulphite modification, along with modified DNA from
cell lines, SiHa (methylation negative) and CaSki (methylation
positive). Direct sequencing revealed heterogeneous methyla-
tion at the CpGs, which could not be captured from McrBCimers and LCR primers respectively analyzed by electrophoresis through a 1.5%
C digested Siha amplicon, HS is HpaII digested amplicon, MT1, 2 and 3 are
2 and 3 are the same samples digested with HpaII. The last lane contains a 50 bp
pGs as predicted by McrBC and HpaII restriction digestion.
Table 1
Summary of methylation status as detected by HpaII and McrBC
Subject Cervical status HpaII McrBC
1 0 UM M
2 0 UM M
3 0 UM M
4 0 UM M
5 0 UM UM
6 0 UM UM
7 0 UM UM
8 0 UM UM
9 0 UM UM
10 0 UM M
11 0 UM UM
12 0 UM UM
13 0 M M
14 0 M UM
15 0 M UM
16 1 UM M
17 1 UM M
18 1 UM M
19 1 UM M
20 1 UM M
21 1 UM M
22 1 UM M
23 1 UM M
24 1 UM M
25 1 UM M
26 1 UM M
27 1 UM M
28 1 UM M
29 1 UM UM
30 1 UM UM
31 1 UM UM
32 1 UM UM
33 1 UM UM
34 1 UM UM
35 1 UM M
36 1 UM UM
37 1 UM UM
38 1 UM M
39 1 UM M
40 1 UM M
41 1 M M
42 1 M M
43 1 M M
44 1 M M
45 1 M M
46 1 M M
47 1 M M
46 1 M M
49 1 M M
50 1 M M
51 1 M M
52 1 M M
53 1 M M
54 1 M M
55 1 M M
56 1 M UM
57 1 M UM
58 1 M UM
59 1 M UM
60 1 M UM
61 1 M UM
62 1 M UM
63 1 M UM
64 1 M UM
Table 1 (continued)
Subject Cervical status HpaII McrBC
65 1 M UM
66 1 M UM
67 1 M UM
68 1 M UM
69 1 M UM
70 1 M UM
71 1 M UM
72 1 M UM
Observations are termed as UM, unmethylated; M, methylated: 0 indicates
normal sample; 1 indicates malignant samples.
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corresponding to sequenced LCR of modified HPV16 DNA
(intact E2) is shown in Fig. 2.
Sequencing results revealed variations in the level of
methylation of the 11 CpGs in the LCR, among the samples
analyzed. The frequency of cytosine methylation was strikingly
low among most samples at four positions 7535, 7579, 7683
and 7862 in the enhancer region out of the 6 CpGs present in
this region, excepting CaSki that we reconfirmed to harbor
methylation at all 11 CpGs. Only one sample was found to be
methylated at 7535 and 7862 (7.7%; 1/13 each), two samples at
7683 (15.4%; 2/13) and none was found to be methylated at
7579. Of the remaining two positions, 7554 and 7677,
methylation was lower at 7554 (38.5%, 5/13) compared to
position 7677 (46.2%; 6/13). Of the 5 CpGs proximal to the
P97 promoter, methylation was found to vary between 60 and
85%. Positions 37 and 58 recorded equivalent and the highest
proportion of methylation (84.5%; 11/13) followed by
positions 52 (72.7%; 8/13), 43 (69.2%; 9/13), and 31
(61.5%; 8/13 each). Thus CpG methylation was more prevalent
in the promoter region (particularly at E2 binding sites),
although we were unable to statistically justify our findings in
view of the small sample size analyzed by sequencing of LCR
(Table 2).
Discussion
This is the first report showing an association of E2BS-I
CpG methylation at nt 58 in the LCR of HPV16 genomes
harboring intact E2, with CaCx development based on analysis
of clinical samples. The observation could probably be related
to that reported by Thain et al. (1996) that the E2 protein's
capacity to bind E2BS in vitro is inhibited by methylation of
these cytosines leading to enhanced viral oncogene expression.
Such overrepresentation of E2BS methylation in malignant
samples compared to the controls, is in contrast to that
reported by Badal et al. (2003) of a progressive lessening in
the degree of CpG methylation as lesions progressed to CaCx.
However, the involvement of increased LCR-E6 methylation
along with E2BS-I methylation appeared to be controversial.
Such methylation was not overrepresented among the CaCx
cases compared to controls and irrespective of E2BS-I
methylation. However, among CaCx cases, LCR-E6 methyla-
tion was higher among cases lacking E2BS-I methylation
Fig. 2. Bi-sulphite sequencing of samples which were found to harbor LCR-E6 methylation by McrBC restriction digestion using primer 5 (nt −7465–115) revealed
clustering of methyl CpGs at SpI binding site (nt −31), E2BS-II (nt −37, 43), and E2BS-1 (nt −52, 58). The upper panel depicts E2 and Spl binding sequences. The
lower panel shows sequencing results of three methylated cancer samples T132, T50 and T121.
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substantiates the potential role played by E2BS-I (nt-58)
methylation next to P97 in mediating susceptibility to CaCx in
individuals harboring HPV16 with intact E2.Table 2
Methylation status of CpGs within LCR of HPV16 in malignant samples
Samples HpaII McrBC Methylation of CpG at position
7535 7554 7579 76
T132 M M − + − +
T14 M M − − − −
T50 M M − + − +
TH128 M M − − − −
T10 M M + + − +
T121 M M − + − +
SST18 M M − − − −
T26 M M − − − +
TH150 M M − − − −
SST 11 M M − + − +
TSN1 UM M − − − −
T135 UM M − − − −
T38 UM M − − − −
UM denotes unmethylated; M denotes methylated.E2's ability to activate transcription is inhibited by the
global methylation of CpG dinucleotides in E2-responsive
transcriptional templates or when only the CpG dinucleotides
within the E2BSs of a transcriptional template are methylated,77 7683 7862 31 37 43 52 58
− − + + + − +
− − + + + − +
− − + + + + +
− − − + − + +
+ − + + + − +
+ − + + + + +
− − − + − + +
− − + + + + +
− − − + + − +
− − + + + + +
− + + + + + +
− − − − − − −
− − − − − + −
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sequencing analysis of CpGs in the LCR harboring E2BSs
and other transcription factor binding sites were almost in line
with earlier observations made by Badal et al. (2003) and
Kalantari et al. (2004). Methylation status of the LCR region
showed absence of or low cytosine methylation at positions
7535, 7579, 7683 and 7862. The first three of such sites are
located in close proximity to important AP1 and NF1
(transcription factor binding sites) sites of the promoter. The
site 7862 coincides with the viral replication origin between
two nucleosomes, close to CDP, AP1 sites and part of E2BS
that activates DNA replication. Methylation was found to be
concentrated at a few positions 31, 37, 43, 52 and 58, which
lie within the SpI binding site and E2BS proximal to the
promoter region. Of these, position 31 is within the SpI
binding site, positions 37 and 43 are within the second E2BS,
while 52 and 58 are within the first E2BS next to the P97
promoter at the 3′ end of LCR. Thus, methyl CpG mapping of
our samples revealed a distinct proneness towards hyper-
methylation of such sites in the LCR, specifically within the
E2BSs. Since methylation of E2BS is known to displace E2
protein, which is a repressor of P97 promoter, our findings
have important bearing on alternative mechanism of loss of
E2 repression that could lead to sustained E6/E7 expression
under conditions where episomal and integrated forms of
HPV16 infection coexist (Matsukura et al., 1989), in cases
harboring episomal HPV16 (Cullen et al., 1991) or those cases
that harbor tandemly repeated viral genomes within the host
genome. All of these viral pathogenic conditions are known to
portray intact E2 gene.
We performed direct sequencing of amplicons generated
from bisulfite modified DNA in this study, as against
sequencing cloned amplicons. Such analysis revealed hetero-
geneous methylation at the CpGs, i.e., overlapping C and T
peaks, as reported earlier by Kalantari et al. (2004). However,
this phenomenon is probably unlikely to affect the relevance of
our findings. Primarily, our aim was to ascertain whether viral
genomes harbored methylated CpGs at key positions in the
LCR region. Hence those samples that had both methylated and
unmethylated E2Bs would potentially be at risk of loss of E2
repressor activity, as a result of inhibition of E2 binding at these
methylated genomes. Therefore, in the background of unmethy-
lated genomes, such methylated genomes could still support
sustained E6 and E7 transcription.
Earlier, we identified that LCR 7450 T>C variation within
the E2BS-IV towards the 5′ end of LCR in samples harboring
undisrupted E2, were significantly associated with HPV16-
positive CaCx, where the virus belonged to the E lineage
(Bhattacharjee and Sengupta, 2006). From the present study we
highlight the involvement of methylation of HPV16 LCR in the
promoter region, particularly E2BSs (E2BS-I at nt 58), in
modulating the oncogenic potential of possibly episomal
HPV16 harboring intact E2 gene. Our study is the first of its
kind, in contrast to earlier studies that addressed the role of
HPV16 methylation in cervical carcinogenesis in the light of
tandem repetition and integration of the virus into the host
genome (Badal et al., 2003, Kalantari et al., 2004). Never-theless, studies are ongoing to ascertain the role of CpG
methylation in CaCx samples harboring viral genomes with
disrupted E2 gene. In conclusion, our finding of the over-
representation of E2BS-I methylation in the LCR of HPV16-
positive cervical cancers harboring intact E2 gene, besides
providing a mechanistic insight, could be useful in identifying
those at risk of CaCx development.
Materials and methods
Samples and subjects
We analyzed DNA samples comprised of a panel of 57
cases and 15 cytologically normal controls all HPV16-positive,
and harboring intact E2, as characterized earlier (Bhattacharjee
and Sengupta, 2006). The malignant samples (histopathologi-
cally confirmed invasive squamous cell carcinomas and
clinically diagnosed as tumor stage III and above as per
FIGO classification) were derived from married subjects,
attending a cancer referral hospital (Cancer Centre Welfare
Home and Research Institute, South 24 Parganas, West Bengal,
India). The control samples were normal cervical scrapes
confirmed by Pap smear test and derived from married women
with no previous history of cervical dysplasia/malignancy.
These women were attending a Reproductive and Child Health
Clinic (Child in Need Institute, South 24 Parganas, West
Bengal, India) for routine contraception and reproductive
healthcare counselling. All samples (biopsy tissues and
cervical scrapes) were collected from the participants with
informed consent approved by the institutional ethical
committee for human experimentation. Details regarding
subjects, samples, and DNA isolation are described elsewhere
(Bhattacharjee and Sengupta, 2006).
Determination of methylation status of HPV16 DNA by
restriction enzyme digestion and PCR
In order to determine the methylation status of the E2BS-I
[50-ACCGAAACCGGT-61], proximal to P97 promoter for
HPV16 E2-positive samples, HpaII/MspI (New England
Biolabs) overnight restriction digestion using 10 units of
enzyme per 100 ng DNA was performed, followed by PCR
analysis using primers LCR F-GCT TGT GTA ACT ATT
GTG TCA and LCR R: GTC CAG AAA CAT TGC AGT
TCT (Tornesello et al., 2000) amplifying nt 7289–114. The
PCR was initiated at 94 °C for 5 min, followed by 35
amplification cycles (denaturation at 94 °C for 15 s, annealing
at 55 °C for 45 s and extension at 72 °C for1 min) with final
extension at 72 °C for 5 min. The reaction mixture (20 μl)
contained 10 ng digested DNA, 10 ng primers, 50 mM KCl,
1.5 mM MgCl2, 50 mM Tris–HCl (pH 8.3), 50 mM
(NH4)2SO4, 25 μM of each dNTP and 1 U of thermostable
DNA Polymerase (Roche Diagnostics). Digested SiHa and
CaSki DNA (10 ng each) were used as negative and positive
controls, since the former harboring only one viral genome is
know to lack methyl CpGs in the entire enhancer-promoter
region. In case of the latter, most of the 500 copies of HPV16
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methylated in this region (Badal et al., 2003).
LCR-E6 methylation was determined for the same set of
samples by McrBC (New England Biolabs) overnight restric-
tion digestion using 10 units of the enzyme per 50 ng DNA,
followed by subsequent PCR amplification using primers LCR
F-GCT TGT GTA ACT ATT GTG TCA and E6 R: CGT GTT
CTT GAT GAT CTG CA amplifying nt 7289–540.The PCR
program and conditions remained the same as that used for
HpaII/MspI analysis.
Mapping of methylated CpGs in the LCR of HPV16 by bisulfite
modification of DNA samples, PCR and direct sequencing of
amplicons
DNA from a randomly selected subset of 13 methylated
(based on McrBC restriction digestion and PCR) malignant
samples harboring undisrupted HPV16 E2, and two cervical
cancer cell lines SiHa and CasKi were subjected to bisulphite
sequencing. Bisulphite treatment (Herman et al., 1996) was
carried out using 500 ng to 1000 ng DNA in a total volume of
50 μl in TE buffer. DNA was denatured with 5 μl of 3 M
NaOH at 37 °C for 30 min. After denaturation 510 μl of
3.9 mM NaHSO3, 30 μl of 10 mM hydroquinone and 610 μl
of water were added and incubated at 55 °C for 16 h. Modified
DNAwas de-salted using Wizard DNA clean up kit (Promega)
and de-sulphonated with 5 μl 3 M NaOH at 37 °C for 15 min.
The DNA was precipitated by addition of 16.5 μl 10 M
CH3COONH4 and 214.5 μl 100% ethanol, washed with 70%
ethanol, vacuum-dried and dissolved in 10–15 μl TE buffer.
The modified DNA was amplified using primers 4F-TAT GTT
TTT TGG TAT AAA ATG TGT TTT T and 4R-TAA ATT
AAT TAA AAC AAA CCA AAA ATA TAT (positions 7465–
7732); 5F-TAA GGT TTA AAT TTT TAA GGT TAA TTA
AAT and 5R-ATC CTA AAA CAT TAC AAT TCT CTT TTA
ATA (positions 7748–115) (Kalantari et al., 2004). The PCR
was initiated at 94 °C for 5 min, followed by 40 amplification
cycles (denaturation at 94 °C for 10 s, annealing at 50 °C for
45 s and extension at 68 °C for1 min) with final extension at
68 °C for 7 min. The reaction mixture (25 μl) contained 30 ng
modified DNA, 50 ng primers, 50 mM KCl, 2 mM MgCl2,
50 mM Tris–HCl (pH 8.3), 50 mM (NH4)2SO4, 25 μM of
each dNTP and 1.25U of FastStart DNA Polymerase (Roche
Diagnostics). PCR products were verified by running on
agarose gel and direct sequencing was carried out using the
same set of primers as described earlier (Bhattacharjee and
Sengupta, 2006).
Statistical analysis
The associations of HPV16 promoter methylation with CaCx
were determined using Fisher's Exact Test and the risk for
associations were determined using Odds Ratio (OR) and 95%confidence interval (CI). A p value of less than 0.05 was
considered as statistically significant.
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